leisure time -WSS

leisure time

author：comprehensive 2025-09-03 09:26:49 - browse：2

How do cancer drugs work? What makes biotech stocks go up? And why are venture capitalists so optimistic?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Andrew Joseph joins us to explain the decades-old cancer-treating technology that had its star turn at this week’s big oncology conference in Europe. We also discuss the latest news in the life sciences, including the future of Alzheimer’s disease treatment, a multibillion-dollar deal, and the return of the biotech mega-round.

For more on what we cover, here’s STAT’s coverage of the European Society for Medical Oncology meeting; here’s more on Roivant Sciences; here’s the latest on biotech venture capital; here’s more on the latest Alzheimer’s data; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： The high cost of giving birth even with insurance
Next article： Biotech investment managers search for lucrative opportunities

WSS

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Medicare says breakthrough device reimbursement rule to come by summer

Making AI in medicine accessible to smaller, and rural hospitals

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Researchers on aging grapple with how to calculate biological age

focus

leisure time

focus

Jerome Adams on the need for new antivirals for Covid

Brain worms: The science behind RFK Jr.'s parasitic infection

Peter Hotez and the public health issue of online harassment

Sanofi strikes deal with Novavax, boosting the vaccine maker

Drug repurposing or repositioning? The language matters

Sanofi strikes deal with Novavax, boosting the vaccine maker

Walensky prepares to leave CDC — and Congress — behind

Sanofi strikes deal with Novavax, boosting the vaccine maker

Wildfire smoke exposes gaps in outdoor worker protections

'Patient friction coefficient' can gauge a clinical trial's patient burden

focus

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Readout LOUD podcast: What to know about H5N1 bird flu

Medicare says breakthrough device reimbursement rule to come by summer

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Telehealth startups turn to complex chronic diseases

focus

focus

hotspot

entertainment